Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments

Karin Schreiber; Donald A Rowley; Gert Riethmüller; Hans Schreiber

doi:10.1016/j.hoc.2006.03.001

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments

Hematol Oncol Clin North Am. 2006 Jun;20(3):567-84. doi: 10.1016/j.hoc.2006.03.001.

Authors

Karin Schreiber¹, Donald A Rowley, Gert Riethmüller, Hans Schreiber

Affiliation

¹ Department of Pathology, The University of Chicago, IL 60637, USA. hszz@midway.uchicago.edu

PMID: 16762725
DOI: 10.1016/j.hoc.2006.03.001

Abstract

Experimental research on the immune response to transplanted tumors has led to pioneering discoveries that laid many of the foundations for the current field of immunology. Experimental research in oncology has proven that murine and human tumors have antigens that are truly cancer specific. This article discusses research investigating how can antigens on cancer cells be used to help eradicate cancer.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animal Experimentation
Animals
Drug Evaluation, Preclinical / methods*
Humans
Immunotherapy / methods*
Neoplasms / therapy*
Therapeutic Human Experimentation

Abstract

Publication types

MeSH terms

Grants and funding